Mental illnesses such as anxiety and depression are being diagnosed with increasing frequency. At the same time, treatment is frequently dependent on legacy drugs that oftentimes to do not work well, have drug interactions, or can lead to addiction or dependence. New therapies are also available, yet they they are systemic and can also have drug interactions and unfavorable side effects. New therapies are needed, especially those with more direct delivery to the relevant regions of the brain. Shawn Singh, CEO of VistaGen, describes their new drug candidates that target depression and anxiety. The novel compounds are delivered as nasal sprays, providing direct interaction with neurological pathways in the olfactory bulb that connect directly to the regions of the brain that affect mood and anxiety. These candidate therapeutics are less likely to drive side effects due to the low levels delivered and their direct interaction with the brain.
 
 VistaGen
www.vistagen.com
www.twitter.com/VistaGen
www.facebook.com/VistaGen